Glucosylceramidase precursor
Glucosylceramidase precursor Brand names, Glucosylceramidase precursor Analogs
Glucosylceramidase precursor Brand Names Mixture
- No information avaliable
Glucosylceramidase precursor Chemical_Formula
C2532H3854N672O711S16
Glucosylceramidase precursor RX_link
http://www.rxlist.com/cgi/generic2/imiglucerase.htm
Glucosylceramidase precursor fda sheet
Glucosylceramidase precursor msds (material safety sheet)
Glucosylceramidase precursor Synthesis Reference
No information avaliable
Glucosylceramidase precursor Molecular Weight
55597.4
Glucosylceramidase precursor Melting Point
No information avaliable
Glucosylceramidase precursor H2O Solubility
No information avaliable
Glucosylceramidase precursor State
Liquid
Glucosylceramidase precursor LogP
-0.168
Glucosylceramidase precursor Dosage Forms
Powder for solution; Solution (IV injection)
Glucosylceramidase precursor Indication
For the treatment of Gaucher's disease (deficiency in glucocerebrosidase)
Glucosylceramidase precursor Pharmacology
Gaucher disease is characterized by a functional deficiency in Beta-glucocerebrosidase enzymatic activity and the resultant accumulation of lipid glucocerebroside in tissue macrophages which become engorged and are termed Gaucher cells. Gaucher cells are typically found in liver, spleen and bone marrow. This can lead to an enlarged spleen and liver (hepatosplenomegaly). Secondary hematologic sequelae include severe anemia and thrombocytopenia. Injections of imiglucerase into Gaucher disease patients leads to elevated serum levels of the enzyme and reduction in the accumulation of glucocerebroside leading to reduced anemia and thrombocytopenia, reduced spleen and liver size, and decreased cachexia
Glucosylceramidase precursor Absorption
No information avaliable
Glucosylceramidase precursor side effects and Toxicity
No information avaliable
Glucosylceramidase precursor Patient Information
No information avaliable
Glucosylceramidase precursor Organisms Affected
Humans and other mammals
